Centessa Pharmaceuticals plc (NASDAQ:CNTA) Position Raised by Adage Capital Partners GP L.L.C.

Adage Capital Partners GP L.L.C. boosted its position in Centessa Pharmaceuticals plc (NASDAQ:CNTA) by 22.0% in the fourth quarter, HoldingsChannel.com reports. The firm owned 5,119,027 shares of the company’s stock after purchasing an additional 924,027 shares during the quarter. Adage Capital Partners GP L.L.C.’s holdings in Centessa Pharmaceuticals were worth $85,744,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD increased its holdings in shares of Centessa Pharmaceuticals by 14.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,364,392 shares of the company’s stock valued at $89,854,000 after buying an additional 685,371 shares in the last quarter. Franklin Resources Inc. boosted its position in shares of Centessa Pharmaceuticals by 0.3% in the 4th quarter. Franklin Resources Inc. now owns 2,308,546 shares of the company’s stock valued at $38,668,000 after purchasing an additional 6,000 shares during the period. Affinity Asset Advisors LLC boosted its position in shares of Centessa Pharmaceuticals by 13.5% in the 4th quarter. Affinity Asset Advisors LLC now owns 1,095,924 shares of the company’s stock valued at $18,357,000 after purchasing an additional 130,312 shares during the period. Lord Abbett & CO. LLC purchased a new position in Centessa Pharmaceuticals in the 3rd quarter worth about $4,305,000. Finally, Trexquant Investment LP raised its holdings in Centessa Pharmaceuticals by 52.8% during the 4th quarter. Trexquant Investment LP now owns 261,184 shares of the company’s stock worth $4,375,000 after buying an additional 90,233 shares during the period. 82.01% of the stock is owned by institutional investors.

Insider Activity at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, insider David M. Chao sold 7,000 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $17.17, for a total value of $120,190.00. Following the completion of the sale, the insider now directly owns 225,007 shares in the company, valued at $3,863,370.19. The trade was a 3.02 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Gregory M. Weinhoff sold 11,742 shares of the business’s stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $16.47, for a total transaction of $193,390.74. Following the completion of the sale, the insider now directly owns 159,782 shares of the company’s stock, valued at $2,631,609.54. This represents a 6.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 213,824 shares of company stock valued at $3,530,601. 11.59% of the stock is owned by corporate insiders.

Centessa Pharmaceuticals Stock Up 2.8 %

CNTA stock opened at $13.03 on Thursday. The company has a 50 day moving average of $14.54 and a two-hundred day moving average of $15.90. The company has a market cap of $1.74 billion, a price-to-earnings ratio of -8.52 and a beta of 1.53. Centessa Pharmaceuticals plc has a 12-month low of $7.75 and a 12-month high of $19.09. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings data on Monday, March 24th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.04. On average, equities analysts anticipate that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. TD Cowen initiated coverage on shares of Centessa Pharmaceuticals in a report on Tuesday, January 7th. They issued a “buy” rating for the company. Guggenheim reaffirmed a “buy” rating and issued a $28.00 price objective on shares of Centessa Pharmaceuticals in a research note on Wednesday, March 26th. Morgan Stanley reiterated an “overweight” rating and set a $27.00 price objective on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. Finally, Piper Sandler started coverage on Centessa Pharmaceuticals in a report on Monday, March 31st. They issued an “overweight” rating and a $38.00 target price for the company. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $27.71.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.